These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 38170429)

  • 41. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
    Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
    Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide.
    Flies CM; Friedrich M; Lohmann P; van Garderen KA; Smits M; Tonn JC; Weller M; Galldiks N; Snijders TJ
    Neuro Oncol; 2024 May; 26(5):902-910. PubMed ID: 38219019
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multimodal assessment of disease activity in glioblastoma : A single center experience.
    Tinchon A; Marhold F; Calabek-Wohinz B; Hainz K; Tesar-Pelz M; Minear G; Freydl E; Blauensteiner K; Heinz G; Oberndorfer S
    Wien Klin Wochenschr; 2021 Nov; 133(21-22):1148-1154. PubMed ID: 33877437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early imaging marker of progressing glioblastoma: a window of opportunity.
    Gatson NTN; Bross SP; Odia Y; Mongelluzzo GJ; Hu Y; Lockard L; Manikowski JJ; Mahadevan A; Kazmi SAJ; Lacroix M; Conger AR; Vadakara J; Nayak L; Chi TL; Mehta MP; Puduvalli VK
    J Neurooncol; 2020 Jul; 148(3):629-640. PubMed ID: 32602020
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.
    Gállego Pérez-Larraya J; Lahutte M; Petrirena G; Reyes-Botero G; González-Aguilar A; Houillier C; Guillevin R; Sanson M; Hoang-Xuan K; Delattre JY
    Neuro Oncol; 2012 May; 14(5):667-73. PubMed ID: 22492961
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Neurologic Assessment in Neuro-Oncology (NANO) Scale as an Assessment Tool for Survival in Patients With Primary Glioblastoma.
    Ung TH; Ney DE; Damek D; Rusthoven CG; Youssef AS; Lillehei KO; Ormond DR
    Neurosurgery; 2019 Mar; 84(3):687-695. PubMed ID: 29618103
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.
    Nayak L; DeAngelis LM; Brandes AA; Peereboom DM; Galanis E; Lin NU; Soffietti R; Macdonald DR; Chamberlain M; Perry J; Jaeckle K; Mehta M; Stupp R; Muzikansky A; Pentsova E; Cloughesy T; Iwamoto FM; Tonn JC; Vogelbaum MA; Wen PY; van den Bent MJ; Reardon DA
    Neuro Oncol; 2017 May; 19(5):625-635. PubMed ID: 28453751
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group.
    Karschnia P; Dono A; Young JS; Juenger ST; Teske N; Häni L; Sciortino T; Mau CY; Bruno F; Nunez L; Morshed RA; Haddad AF; Weller M; van den Bent M; Beck J; Hervey-Jumper S; Molinaro AM; Tandon N; Rudà R; Vogelbaum MA; Bello L; Schnell O; Grau SJ; Chang SM; Berger MS; Esquenazi Y; Tonn JC
    Neuro Oncol; 2023 Sep; 25(9):1672-1685. PubMed ID: 37253096
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early response assessment of glioma patients to definitive chemoradiotherapy using chemical exchange saturation transfer imaging at 7 T.
    Meissner JE; Korzowski A; Regnery S; Goerke S; Breitling J; Floca RO; Debus J; Schlemmer HP; Ladd ME; Bachert P; Adeberg S; Paech D
    J Magn Reson Imaging; 2019 Oct; 50(4):1268-1277. PubMed ID: 30864193
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of neurological function using the National Institute of Health Stroke Scale in patients with gliomas.
    Zeitlberger AM; Flynn MC; Hollenstein M; Hundsberger T
    Neurooncol Pract; 2021 Dec; 8(6):699-705. PubMed ID: 34777839
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-angiogenic therapy for high-grade glioma.
    Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.
    Wollring MM; Werner JM; Bauer EK; Tscherpel C; Ceccon GS; Lohmann P; Stoffels G; Kabbasch C; Goldbrunner R; Fink GR; Langen KJ; Galldiks N
    Neuro Oncol; 2023 May; 25(5):984-994. PubMed ID: 36215231
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Deep learning automates bidimensional and volumetric tumor burden measurement from MRI in pre- and post-operative glioblastoma patients.
    Nalepa J; Kotowski K; Machura B; Adamski S; Bozek O; Eksner B; Kokoszka B; Pekala T; Radom M; Strzelczak M; Zarudzki L; Krason A; Arcadu F; Tessier J
    Comput Biol Med; 2023 Mar; 154():106603. PubMed ID: 36738710
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disease Assessments in Patients with Glioblastoma.
    Phillips KA; Kamson DO; Schiff D
    Curr Oncol Rep; 2023 Sep; 25(9):1057-1069. PubMed ID: 37470973
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparing available criteria for measuring brain metastasis response to immunotherapy.
    Qian JM; Mahajan A; Yu JB; Tsiouris AJ; Goldberg SB; Kluger HM; Chiang VLS
    J Neurooncol; 2017 May; 132(3):479-485. PubMed ID: 28275886
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    Deuschl C; Kirchner J; Poeppel TD; Schaarschmidt B; Kebir S; El Hindy N; Hense J; Quick HH; Glas M; Herrmann K; Umutlu L; Moenninghoff C; Radbruch A; Forsting M; Schlamann M
    Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):593-601. PubMed ID: 29282517
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early Pseudoprogression following Chemoradiotherapy in Glioblastoma Patients: The Value of RANO Evaluation.
    Linhares P; Carvalho B; Figueiredo R; Reis RM; Vaz R
    J Oncol; 2013; 2013():690585. PubMed ID: 24000284
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
    Huang RY; Rahman R; Ballman KV; Felten SJ; Anderson SK; Ellingson BM; Nayak L; Lee EQ; Abrey LE; Galanis E; Reardon DA; Pope WB; Cloughesy TF; Wen PY
    Clin Cancer Res; 2016 Feb; 22(3):575-81. PubMed ID: 26490307
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic Relevance of Treatment Failure Patterns in Pediatric High-Grade Glioma: Is There a Role for a Revised Failure Classification System?
    Lucas JT; Cooper DA; Hwang S; Tinkle C; Li X; Li Y; Orr B; Merchant TE; Broniscer A
    Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):450-458. PubMed ID: 28871996
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma.
    Kebir S; Rauschenbach L; Gielen GH; Schäfer N; Tzaridis T; Scheffler B; Giordano FA; Lazaridis L; Herrlinger U; Glas M
    J Clin Neurosci; 2018 Jul; 53():255-258. PubMed ID: 29754968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.